S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
NASDAQ:AMYT

Amryt Pharma News Headlines

$10.52
+0.24 (+2.33%)
(As of 01/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$10.14
$10.58
50-Day Range
$9.44
$11.59
52-Week Range
$9.17
$15.44
Volume
63,271 shs
Average Volume
132,467 shs
Market Capitalization
$672.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.58
Get Amryt Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMYT and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Amryt Pharma Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AMYT
News Sentiment

0.89

0.34

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AMYT Articles
This Week

3

0

AMYT Articles
Average Week



Amryt Pharma (NASDAQ:AMYT) News Headlines Today

SourceHeadline
MarketBeat logoAmryt Pharma (NASDAQ:AMYT) Shares Gap Up to $10.00
americanbankingnews.com - January 21 at 11:34 AM
nasdaq.com logoAmryt Pharma PLC Sponsored ADR (AMYT) Surges 5.5%: Is This an Indication of Further Gains?
nasdaq.com - January 18 at 9:17 AM
MarketBeat logoAmryt Pharma (NASDAQ:AMYT) Trading Up 5.2%
americanbankingnews.com - January 14 at 3:44 PM
finance.yahoo.com logoAmryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide
finance.yahoo.com - January 11 at 9:46 AM
MarketBeat logoAmryt Pharma (NASDAQ:AMYT) Sees Strong Trading Volume
americanbankingnews.com - January 7 at 2:38 PM
finance.yahoo.com logoThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
finance.yahoo.com - January 4 at 7:50 AM
finance.yahoo.com logoAmryt (AMYT) Skin Disorder NDA Review Gets 3 Months Extension
finance.yahoo.com - November 24 at 1:04 PM
proactiveinvestors.com logoAmryt Pharma drug application review with FDA extended three months
proactiveinvestors.com - November 23 at 10:19 AM
finance.yahoo.com logoAmryt Pharma PLC Sponsored ADR (AMYT) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 3 at 12:45 PM
bizjournals.com logoPharma sales rep sentenced in Aegerion drug misbranding probe
bizjournals.com - November 1 at 1:20 PM
finance.yahoo.com logoEarnings Preview: Amryt Pharma PLC Sponsored ADR (AMYT) Q3 Earnings Expected to Decline
finance.yahoo.com - October 28 at 7:14 PM
finance.yahoo.com logoAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
finance.yahoo.com - October 20 at 11:52 AM
finance.yahoo.com logoAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
finance.yahoo.com - October 19 at 7:58 AM
finance.yahoo.com logoAmryt Issues Ordinary Shares and Total Voting Rights
finance.yahoo.com - August 19 at 3:45 AM
markets.businessinsider.com logoPre-market Movers: VRPX, GLG, PTIX, GLBS, AMYT, ALC…
markets.businessinsider.com - August 18 at 7:41 AM
finance.yahoo.com logoAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
finance.yahoo.com - August 9 at 7:55 AM
finance.yahoo.com logoAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
finance.yahoo.com - August 5 at 12:19 PM
sg.finance.yahoo.com logoQuestex’s Digital Pharma East to Unite the Pharma Marketing Community In-Person September 28-30 in Philadelphia
sg.finance.yahoo.com - July 29 at 11:16 PM
sg.finance.yahoo.com logoGlobal Pharmaceutical Glass Packaging Market to Reach $26.6 Billion by 2027
sg.finance.yahoo.com - July 29 at 11:16 PM
finance.yahoo.com logoResult of General Meetings
finance.yahoo.com - July 28 at 2:14 PM
finance.yahoo.com logoAmryt (AMYT) NDA for Skin Disorder Drug Gets Priority Review
finance.yahoo.com - June 4 at 1:40 PM
proactiveinvestors.com logoAmryt Pharma hopeful of winning fast-track US approval for breakthrough skin gel
proactiveinvestors.com - March 31 at 8:51 AM
finance.yahoo.com logoAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
finance.yahoo.com - March 31 at 3:50 AM
proactiveinvestors.com logoAmryt Pharma encouraged by study of lomitapide in Familial Chylomicronaemia Syndrome
proactiveinvestors.com - March 30 at 7:48 AM
in.finance.yahoo.com logoAmryt Pharma plc (AMYT)
in.finance.yahoo.com - March 17 at 7:24 AM
proactiveinvestors.com logoAmryt Pharma inks Canada distribution agreement for Myalepta drug
proactiveinvestors.com - March 8 at 7:46 AM
finance.yahoo.com logoAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada
finance.yahoo.com - March 8 at 7:46 AM
finance.yahoo.com logoAmryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
finance.yahoo.com - December 17 at 7:57 AM
proactiveinvestors.com logoAmryt Pharma gets marketing approval in Brazil for specialist cholesterol drug Lojuxta
proactiveinvestors.com - December 9 at 7:39 AM
finance.yahoo.com logoAmryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
finance.yahoo.com - December 9 at 2:18 AM
proactiveinvestors.com logoAmryt Pharma ups forecasts as sales accelerate in third quarter
proactiveinvestors.com - November 5 at 5:35 PM
finance.yahoo.com logoAmryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance
finance.yahoo.com - November 5 at 7:33 AM
finance.yahoo.com logoAMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA
finance.yahoo.com - October 29 at 7:24 AM
msn.com logoMIDAS SHARE TIPS UPDATE: Amryt drug may be winner
msn.com - October 16 at 4:47 PM
finance.yahoo.com logoExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
finance.yahoo.com - September 21 at 7:59 AM
nasdaq.com logoAMPE Says Ampion Improves COVID-19 Symptoms, AMYT At Ease, ITCI Impresses With Depression Trial Data
nasdaq.com - September 10 at 7:28 AM
finance.yahoo.com logoPOSITIVE TOP LINE RESULTS FROM PHASE 3 TRIAL IN EB
finance.yahoo.com - September 9 at 9:03 AM
finance.yahoo.com logoAMRYT ANNOUNCES Q2 2020 RESULTS AND ISSUES POSITIVE REVENUE GUIDANCE FOR FY 2020
finance.yahoo.com - August 6 at 8:25 AM
finance.yahoo.com logoAMRYT TO HOST KEY OPINION LEADER CALL ON EPIDERMOLYSIS BULLOSA DISEASE LANDSCAPE
finance.yahoo.com - July 29 at 9:18 AM
Get Amryt Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMYT and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.